Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Development of Single-Cycle Replicable Human Immunodeficiency Virus 1 Mutants Publisher Pubmed



Zabihollahi R1, 2 ; Sadat SM1, 3 ; Vahabpour R1 ; Aghasadeghi MR1 ; Memarnejadian A1 ; Ghazanfari T4 ; Salehi M2 ; Rezaei A2 ; Azadmanesh K1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Hepatitis and AIDS Dept., Pasteur Institute of Iran, Tehran, Iran
  2. 2. Medical School, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Science and Research branch, Islamic Azad University, Tehran, Iran
  4. 4. Immunology Dept., Medical School, Shahed University, Tehran, Iran

Source: Acta Virologica Published:2011


Abstract

Non-infectious but antigenic human immunodeficiency virus 1 (HIV-1) particles are essential tool for the research on many topics associated with this virus. Here we report the construction of plasmid containing the HIV-1 genome mutated in the pol gene, which was co-transfected with plasmids expressing the pol gene products reverse transcriptase (RT) and integrase (IN), and the glycoprotein G of vesicular stomatitis virus (VSV-G). The virions produced in HEK 293 T cells were antigenic, but able to replicate only for one cycle, e.g. first generation single-cycle replicable (SCR) virions. The presence of VSV-G in the envelope of these virions had to ensure a wider spectrum of susceptible cell types for the replication of SCR. Replication of the first generation SCR virions in HEK 293T, MT-2, and mouse spleen cells was examined by p24-capture ELISA, syncytium formation assay, and electron microscopy (EM). HEK 293T and MT-2 cell lines showed a similar replication capacity, while primary cultures of mouse spleen cells were much less effective. The infection of MT-2 cells with the first generation of SCR virions yielded the second generation SCR virions, which were non-infectious. Summing up, the HIV-1 SCR virions represent the useful tool for HIV-1 research facilitating a better biological safety. Moreover, considering their antigenic composition and limited replication, SCR virions may be a promising candidate for the vaccine studies.